Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

Bibliographic Details
Main Authors: J.L. Boormans, R. De Wit, G.S. Kulkarni, E.M. Uchio, M. Roumiguié, L.E.M. Krieger, E.A. Singer, D.F. Bajorin, A.M. Kamat, P. Grivas, H.K. Seo, H. Nishiyama, B.R. Konethy, T. Saretsky, H. Li, K. Nam, E. Kapadia, A.V. Balar
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168320333723
Description
ISSN:2666-1683

Similar Items